Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RTRX

Travere Therapeutics (RTRX) Stock Price, News & Analysis

Travere Therapeutics logo

About Travere Therapeutics Stock (NASDAQ:RTRX)

Advanced Chart

Key Stats

Today's Range
$16.25
$16.60
50-Day Range
$24.25
$28.18
52-Week Range
$8.98
$24.96
Volume
1.23 million shs
Average Volume
412,277 shs
Market Capitalization
$840.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive RTRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RTRX Stock News Headlines

Travere Therapeutics Inc.
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

RTRX Stock Analysis - Frequently Asked Questions

Travere Therapeutics, Inc. (NASDAQ:RTRX) announced its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.15. Travere Therapeutics had a negative net margin of 49.13% and a negative trailing twelve-month return on equity of 36.38%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include CVS Health (CVS), Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Novavax (NVAX), TG Therapeutics (TGTX), Dynavax Technologies (DVAX) and Intercept Pharmaceuticals (ICPT).

Company Calendar

Last Earnings
11/05/2020
Today
7/13/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RTRX
CIK
1438533
Fax
N/A
Employees
221
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.46)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$146.43 million
Net Margins
-49.13%
Pretax Margin
N/A
Return on Equity
-36.38%
Return on Assets
-14.90%

Debt

Debt-to-Equity Ratio
0.66
Current Ratio
7.23
Quick Ratio
7.14

Sales & Book Value

Annual Sales
$175.34 million
Price / Sales
4.80
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.15 per share
Price / Book
3.20

Miscellaneous

Outstanding Shares
51,052,000
Free Float
N/A
Market Cap
$840.83 million
Optionable
Not Optionable
Beta
0.67
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:RTRX) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners